The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-published; ~73% dysgeusia the caveat.AML: the menin inhibitor frontline class war — ziftomenib KOMET-007 (CRc 96% NPM1m / 90%KMT2Ar) vs revumenib (frontline CRc 97%; SAVE ORR 88%) — and the gilteritinib-vs-midostaurin FLT3 survival miss (HR 1.02). CLL: BRUIN CLL-322 — pirtobrutinib + venetoclax-rituximab, PFS HR 0.55, first Phase 3 to beat a venetoclax control. LYMPHOMA: frontMIND (tafasitamab+len+R-CHOP, 1L DLBCL, PFS HR 0.75) and EPCORE DLBCL-1 (epcoritamab wins PFS, misses OS). MYELOFIBROSIS: SENTRY (selinexor+rux, SVR35 49.8% vs 28%, symptom co-primary missed). BENIGNHEME: warm AIHA gets two drugs (sovleplenib, nipocalimab) in a disease with no approved therapy; CASGEVY first pediatric gene-editing data. Lightning round, discipline corner (why three 'EHA' myeloma headlines were actually ASCO), and what to watch. Three throughlines: immunotherapy moving earlier andoff-the-shelf, a frontline standard-of-care reset, and the survival misses that set the discipline. Stock reactions qualitative only.pharma, pharmaceutical, hematology, blood cancer, clinicaltrials, biotech, EHA 2026, pharma podcast, The Pharma Closeout
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →